Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.
Vincenzi B, Nannini M, Fumagalli E, Bronte G, Frezza AM, De Lisi D, Spalato Ceruso M, Santini D, Badalamenti G, Pantaleo MA, Russo A, Dei Tos AP, Casali P, Tonini G. Vincenzi B, et al. Among authors: badalamenti g. Oncotarget. 2016 Oct 25;7(43):69412-69419. doi: 10.18632/oncotarget.5136. Oncotarget. 2016. PMID: 26416414 Free PMC article.
Antiblastic drug combinations with ifosfamide: an update.
Fulfaro F, Valerio MR, Badalamenti G, Gebbia N, Russo A. Fulfaro F, et al. Among authors: badalamenti g. Oncology. 2003;65 Suppl 2:21-30. doi: 10.1159/000073354. Oncology. 2003. PMID: 14586143 Review.
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma.
Valerio MR, Tagliaferri P, Raspagliesi F, Fulfaro F, Badalamenti G, Arcara C, Cicero G, Russo A, Venuta S, Guarneri G, Gebbia N. Valerio MR, et al. Among authors: badalamenti g. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:79-85. doi: 10.1111/j.1525-1438.2006.00324.x. Int J Gynecol Cancer. 2006. PMID: 16515572 Clinical Trial.
The role of Aurora-A inhibitors in cancer therapy.
Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G, Colucci G, Adamo V, Santini D, Russo A. Agnese V, et al. Among authors: badalamenti g. Ann Oncol. 2007 Jun;18 Suppl 6:vi47-52. doi: 10.1093/annonc/mdm224. Ann Oncol. 2007. PMID: 17591831 Free article. Review.
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, Del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A. Sperone P, et al. Among authors: badalamenti g. Endocr Relat Cancer. 2010 Apr 21;17(2):445-53. doi: 10.1677/ERC-09-0281. Print 2010 Jun. Endocr Relat Cancer. 2010. PMID: 20410174 Clinical Trial.
PML down-regulation in soft tissue sarcomas.
Vincenzi B, Perrone G, Santini D, Grosso F, Silletta M, Frezza A, Rossi S, Russo A, Rabitti C, Gebbia N, Badalamenti G, Casali P, Muda AO, Dei Tos AP, Tonini G. Vincenzi B, et al. Among authors: badalamenti g. J Cell Physiol. 2010 Sep;224(3):644-8. doi: 10.1002/jcp.22161. J Cell Physiol. 2010. PMID: 20578240
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.
Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, Silvestris N, Berardi R, Masini C, Calipari N, Ottaviani D, Catalano V, Badalamenti G, Giannicola R, Fabbri F, Venditti O, Fratto ME, Mazzara C, Latiano TP, Bertolini F, Petrelli F, Ottone A, Caroti C, Salvatore L, Falcone A, Giordani P, Addeo R, Aglietta M, Cascinu S, Barni S, Maiello E, Tonini G. Santini D, et al. Among authors: badalamenti g. Ann Oncol. 2012 Aug;23(8):2072-2077. doi: 10.1093/annonc/mdr572. Epub 2012 Jan 4. Ann Oncol. 2012. PMID: 22219016 Free article.
158 results